Compare Abbott Laboratories (ABT) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Entegris Inc — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while Entegris Inc trades at $139.93 (market cap $20.57B). The key difference: Abbott Laboratories is far larger — about 8.1× Entegris Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | ENTG | |
|---|---|---|
Market Cap | $166.94B | $20.57B |
Sector | Health | Technology |
52-Week High | $136.62 | $184.00 |
52-Week Low | $82.57 | $68.80 |
Enterprise Value | $193.69B | $23.89B |
Dividend Yield | 2.63% | 0.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ENTG is trading at $135.08, down 7.9% today, with a bearish technical signal and neutral oscillators. The company reported strong Q1 2026 earnings of $0.86 per share, beating estimates, and maintains solid fundamentals with $3.2B revenue and 8.18% net income margin. Recent developments include a strategic cross-licensing agreement for EUV lithography and appointment of a new CFO.
Wall Street maintains a bullish outlook with 65% buy ratings and $178.40 consensus price target, representing 32% upside potential. Key risks include premium valuation (P/E 83.91), semiconductor cycle sensitivity, and execution challenges. The stock offers growth exposure to AI-driven semiconductor demand but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
